2-day In-person Seminar

Tougher Import Rules for FDA Imports in 2016

By Casper Uldriks
Location: Philadelphia, PA   Date: August 11th & 12th, 2016   Time:   9:00 AM to 6:00 PM    |     Venue : Hilton Garden Inn Philadelphia Center City
Register for Seminar     For discounts on multiple registrations, contact customer care at +1-800-385-1607     Register Now

Overview:

FDA's and the Customs and Border Patrol Service (CBP) have become increasingly sophisticated and equally demanding in the submission of information and adherence to government procedures. Firm's that fail to understand and properly execute an import and export program find that their shipment is delayed, detained or refused. In 2016 entries must use the Automated Commercial Environment (ACE) entry filing system or face entry refusals and monetary penalties up to $10,000 per offense. A number of other factors can derail the expectation of a seamless import process. The course covers detailed information about the roles and responsibilities of the various parties with an import operation and how to correct the weakest link(s) in the commercial chain. The course will include tips on how to understand FDA's thinking and offer anecdotal examples of FDA's import program curiosities.


Why should you attend:

What happens when your product is detained? FDA will begin a legal process that can become an expensive business debacle. You must respond fully within short timeframes. This is not the time for you to be on a learning curve. You need to have a plan in place and know what you are doing.

The FDA is steadily increasing the legal and prior notice information requirements. If you do not know what those requirements are and you initiate a shipment, your product is figuratively dead in the water. You must be accurate with the import coding information and understand the automated and human review process. If not, you can expect detained shipments. CBP is implemented a new "Automated Commercial Environment" computer program that changes import logistics and information reporting for FDA regulated products. Your shipment may be stopped before it is even loaded at the foreign port.

What happens when FDA decides you should bring the products back to the port of entry after you received a release but you cannot locate the product that has been sold? CBP may fine you three times the value of the shipment. FDA may have other adverse legal concerns and strategies.

When products are refused, you have different options. Some options may cost more than others. For example, your product can be seized and destroyed by the government. You may be fined if you do not act in a timely manner.

These are common problems that become prohibitively expensive. You should know how to avoid common problems or at least how to mitigate the cost by using established and effective business planning.


Who will benefit:

  • Domestic importers
  • Foreign exporter
  • Initial importers
  • International trade executives
  • Venture Capitalists
  • Marine insurance underwriters
  • Import Brokers
  • Regulatory affairs managers
  • Import / Export consultants
  • In-house counsel
  • Contract specialists
  • Logistics managers
  • Third party establishment inspection entities
  • Sales managers
  • Investors

Agenda

Day One


Lecture 1:

FDA Legal Authority Customs and Border Control (CBP) Import Process FDA Import Process Registration and documentation


Lecture 2:

FDA Import Process (continued)

  • Import Brokers
  • Prior Notice Information
  • CBP and FDA computer programs
  • Import Codes
  • Bonds and Bonded Warehouses
  • FDA "Notice of Action"

Lecture 3:

Import Delays Import Alerts Detention Refusals

Day Two


Lecture 1:

Foreign Inspections FDA 483 - Inspectional Observations


Lecture 2:

FDA Warning Letters and Automatic detention


Lecture 3:

Import Hypothetical FDA Import for Export Program FDA Export Program Export Hypothetical


Lecture 4:

FDA Export Program Special Import Issues

  • Trade Shows
  • Personal Use
  • Compassionate Use

Pricing/Register

August 11th & 12th, 2016

Price: $1,495.00
(Seminar for One Delegate)


**Please note the registration will be closed 2 days (48 Hours) prior to the date of the seminar.

Payment Options      

Want to register by P.O/Check?
We facilitate registration by P.O/Checks!
Complete your registration in just few easy steps:
Please just download, fill out the registration form and send it to us either by email to support@mentorhealth.com or just fax us at 302 288 6884.
Once the form is received and invoice will be generated and sent back to your fax number.
Following this just send us your purchase order by fax at 302 288 6884
Click here to download Registration form
In case you wish to register by using check, please make a check to NetZealous LLC DBA MentorHealth.com and mail it to the below address.
NetZealous LLC,
DBA MentorHealth,
161 Mission Falls Lane,
Suite 216, Fremont, CA 94539, USA
Phone: +1-800-385-1607

Group participations

Get fabulous discounts by participating in groups of two or more.
Send two attendees: Get a discount of 10%!
Send three to six attendees: Get a grand discount of 20%!
Send seven to 10 attendees: Get a great discount of 25%!
Send more than 10 attendees: Get a whopping discount of 30%!
To avail the above group discounts, all the participants should register by making a single payment

Call our representative TODAY on +1-800-385-1607 to have your seats confirmed!


Quick Contact

Toll free: +1-800-385-1607
Email: support@mentorhealth.com

Want to register by Wire Transfer?

Please call any of our representatives on +1-800-385-1607 to help you completed the transfer.

Venue


Location: Philadelphia, PA Hotel: Hilton Garden Inn Philadelphia Center City   1100 Arch St, Philadelphia, PA 19107, United States


Speaker

Casper Uldriks

ex-FDA Expert and former Associate Center Director of CDRH

Casper (Cap) Uldriks, through his firm "Encore Insight LLC," brings over 32 years of experience from the FDA. As an investigator, he was responsible for countless 483s, scores of Warning Letters, injunctions, individual seizures, mass seizures and was coined by industry as FDA's "Darth Vader." He inspected foods, drugs, methadone clinics and clinical investigators, but specialized in the FDA's medical device program. He served as a senior manager in the Office of Compliance and an Associate Center Director for the Center for Devices and Radiological Health. He developed enforcement actions and participated in the implementation of new statutory requirements for FDA. His comments are candid, straightforward and of practical value. He understands how FDA thinks, how it operates and where it is headed. Based on his exceptionally broad experience and knowledge, he can synthesize FDA's domestic and international operational programs, institutional policy and thicket of legal variables into a coherent picture.